Dynavax to Present at Susquehanna Financial Group's Second Annual SIGnificant Options in Healthcare Conference
BERKELEY, Calif., Feb 28, 2008 (BUSINESS WIRE) -- Dynavax Technologies Corporation (Nasdaq:DVAX) announced today Michael S. Ostrach, Vice President and Chief Business Officer, will present an overview of the company at the Susquehanna Financial Group's Second Annual SIGnificant Options in Healthcare Conference on Wednesday, March 5, 2008 at 1:00 p.m. ET (10:00 a.m. PT) in New York City. The presentation will be webcast.
To access the live audio broadcast and the subsequent archived audio recordings of the company presentation, please log onto the company's website at www.dynavax.com under the "Investors'" section.
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our product candidates include: HEPLISAV(TM), a hepatitis B vaccine in Phase 3 partnered with Merck & Co., Inc.; TOLAMBA(TM), a ragweed allergy immunotherapy in Phase 2; a therapy for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B in Phase 1. Our preclinical asthma and COPD program is partnered with AstraZeneca. The NIH partially funds our preclinical work on a vaccine for influenza. SDI funds our colorectal cancer and hepatitis C therapeutic programs, and Deerfield Management has committed funding for our allergy programs. While Deerfield, NIH and SDI provide program support, Dynavax has retained rights to seek strategic partners for future development and commercialization. For more information, please visit http://www.dynavax.com.
SOURCE: Dynavax Technologies Corporation
Dynavax Technologies Corporation Shari Annes, 650-888-0902 Investor Relations sannes@dynavax.com
Copyright Business Wire 2008
News Provided by COMTEX